Mode
Text Size
Log in / Sign up
N/A Completed N=50 Prevention

Scottish Vitamin D Intervention Study

GENE EXPRESSION · Colorectal Cancer
Source: ClinicalTrials.gov NCT04868227 ↗
Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Number of Genes Significantly Associated With 25OHD Blood Vitamin D Level — 629 significant probes (P<0.01)

Summary

AIMS To identify the underlying mechanism by which Vitamin D reduces colorectal cancer risk. OBJECTIVES To demonstrate the effects of vitamin D supplementation on serum vitamin D levels. To demonstrate dynamic changes in gene expression in response to vitamin D. To demonstrate the mechanism underlying the gene-environment interaction of vitamin D, susceptibility genetic variants (risk genes) and colorectal cancer.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Genes Significantly Associated With 25OHD Blood Vitamin D Level
629
PRIMARY
GENE EXPRESSION CHANGE
9
SECONDARY
VITAMIN D STATUS
40
SECONDARY
VITAMIN D STATUS CHANGE
35.85; 89

Eligibility Criteria

Inclusion Criteria

  • Aged 16 years or over.
  • Resident of the United Kingdom

Exclusion Criteria

  • The inability to provide informed consent.
  • Under the age of 16 years.
  • A non-UK resident.
  • Patients who may be at increased risk from rigid sigmoidoscopy:
  • Individuals who are taking anti-coagulation medication.
  • Individuals with platelet disease or other bleeding issues.
  • Individuals with a history of a significant rectal bleed.
  • Suspected or known bowel perforation
  • Anal stenosis
  • Acute peritonitis
  • Colonic necrosis
  • Toxic megacolon
  • Acute severe diverticulitis
  • Diverticular abscess
  • Recent colonic surgery
  • Anal fissure
  • Severe coagulopathy
  • Anticoagulant therapy
  • Severe thrombocytopenia
  • Severe neutropenia
  • Patients who may be at increased risk from Vitamin D supplementation would not be included in the intervention arm but could still be included in the single sample arm:
  • Kidney disease
  • High levels of calcium in the blood
  • Atherosclerosis
  • Sarcoidosis
  • Histoplasmosis
  • Over-active parathyroid gland (hyperparathyroidism)
  • Lymphoma
  • Currently taking thiazide diuretics, digoxin or other cardiac glycosides
  • Known allergy to nuts ( as peanut oil contained within vitamin D preparations)
  • Female subjects of child bearing age who are not taking effective contraception during the period of the trial
  • Patients in whom vitamin D levels may be unpredictable
  • Individuals already established on supplementary Vitamin D.
  • Individuals recently returned to the UK from an overseas holiday.
  • Individuals who have recently lived abroad.
  • Patients on anti-epileptic medication
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04868227). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search